Step 1 of 2
Dopamine receptor–blocking agents are widely used across psychiatric conditions but can place patients at risk for tardive dyskinesia (TD), a potentially persistent movement disorder with meaningful effects on functioning and quality of life. This downloadable slideset reviews TD risk factors, clinical presentation, differential diagnosis, and screening with tools such as AIMS, and examines patient impact and evidence-based management strategies, including the role of FDA-approved VMAT2 inhibitors.